Allakos Reports Phase 3 Data from ENIGMA 2 Study and Phase 2-3 Data from KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

Dec 23, 2021 By MarketDepth

Biotechnology Business Headlines Healthcare Investing What's Hot

Business Update

Allakos Inc. (NASDAQ: ALLK) reported data from its ENIGMA 2 Phase 3 study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis and or eosinophilic duodenitis and KRPYTOS Phase 2/3 study of lirentelimab in patients with biopsy confirmed eosinophilic esophagitis.  “We are deeply disappointed that the studies did not achieve their symptomatic endpoints,” said Robert Alexander, PhD, Chief Executive Officer of Allakos. “The company is grateful to the patients with eosinophilic gastrointestinal diseases (EGIDs) and to the investigators who participated in the ENIGMA and KRYPTOS trials.”

“Although the EGID results are surprising and disappointing, we will continue to analyze the data to understand the results and to determine the path forward for lirentelimab in EGIDs. At present we intend to continue our development efforts with subcutaneous lirentelimab in atopic dermatitis, chronic spontaneous urticaria, and asthma. The atopic dermatitis study is underway and we plan to initiate chronic spontaneous urticaria and asthma studies in 2022 and will continue to advance other programs in our preclinical pipeline.”

Dr. Craig Paterson, MD, Chief Medical Officer of Allakos